RCT (n=36)
randomized
Quantification of specific DNA adducts in myocardial tissue may represent an early biomarker for anthracycline-induced cardiotoxicity.
Answers are grounded in this paper and cite their sources.
DNA adduct quantification merits exploration as an early anthracycline cardiotoxicity biomarker; leaves open human translation and clinical utility.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Hahm et al. (2003) conducted an RCT in Anthracycline cardiomyopathy (n=36). Adriamycin vs. 0.9% saline i.p. was evaluated on DNA adduct formation.
Synapse has enriched 10 related papers. Consider them for comparative context: